Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

TNI BioTech Out-licenses Two Drugs to Hubei Qianjiang Pharma

publication date: Oct 19, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
TNI BioTech of the US has out-licensed the China rights for two R&D-stage cancer treatments to Hubei Qianjiang Pharma. TNI’s technology centers on methionine enkephalin (MENK), a cytokine that stimulates the immune system. In IRT-101, MENK is infused directly into the patient. In IRT-102, the treatment consists of isolating a patient's lymphocytes, incubating them with MENK, and the re-infusing them to fight tumor cells. More details....

Stock Symbols: (PINKSHEETS: TNIB) (SHA: 600568)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners